Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19
Part of paid clinical trials in Durham, North Carolina.
- Sponsor
- Duke University
- Study ID
- NCT04357574
- Status
- Enrolling By Invitation
Conditions
- COVID-19
- Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Telehealth — OTHERpatients have virtual visits with Radiation Oncology providers in lieu of in person clinic visits as a necessary response to COVID-19
Study Details
The primary objective of this research study is to assess Radiation Oncology healthcare providers (i.e. faculty, residents and advanced practice providers (APPs) implementation and perception of telehealth for on treatment patients in lieu of in person on treatment visits during standard of care radiotherapy during COVID-19.
Key Dates
- Start date
- Apr 14, 2020
- Status verified
- Feb 2026
- Primary completion
- Apr 30, 2027
- Completion
- Apr 30, 2027
Study Design
- Enrollment
- 1,000 participants (estimated)
Arms
- Arm: Radiation Oncology ProvidersFaculty physicians, residents and advanced practice providers in the Radiation Oncology Department in Duke University Health System (DUHS)
Primary Outcome Measure
Radiation Oncology providers perception of of telehealth for on treatment patients in lieu of in person on treatment visits during COVID-19 [ Time Frame: 12 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Duke Cancer Center | Durham | North Carolina | 27710 | - |
Find similar trials in Durham, NC
By condition
By specialty
By research site
Related Studies
- Study of the Effect of Innate on the Inflammatory Response to EndotoxinRecruiting · National Institute of Environmental Health Sciences (NIEHS) · Research Triangle Park, North Carolina
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT StudyPHASE3 · Recruiting · Ansun Biopharma, Inc. · Duarte, California
- Pan Tumor Rollover StudyPHASE2 · Recruiting · Bristol-Myers Squibb · Huntsville, Alabama